 | Up a level |
Lucas, Claire M 
ORCID: 0000-0001-6674-7535, Scott, Laura J, Carmell, Natasha, Holcroft, Alison K, Hills, Robert K, Burnett, Alan K and Clark, Richard E ORCID: 0000-0002-1261-3299
(2018)
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.
Blood Advances, 2 (9).
pp. 964-968.
Austin, James A, Jenkins, Rosalind E, Austin, Gemma M, Glenn, Mark A, Dunn, Karen, Scott, Laura, Lucas, Claire M ORCID: 0000-0001-6674-7535 and Clark, Richard E ORCID: 0000-0002-1261-3299
(2019)
Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells.
BIOCHEMICAL JOURNAL, 476 (15).
pp. 2255-2269.
Makela, Eleonora, Pavic, Karolina, Varila, Taru, Salmenniemi, Urpu, Loyttyniemi, Eliisa, Nagelli, Srikar G, Ammunet, Tea, Kahari, Veli-Matti, Clark, Richard E ORCID: 0000-0002-1261-3299, Elo, Laura L et al (show 4 more authors)
(2021)
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
CLINICAL CANCER RESEARCH, 27 (10).
pp. 2848-2860.
Di Mambro, Antonella ORCID: 0009-0003-1157-216X, Arroyo-Berdugo, Yoana ORCID: 0000-0003-3268-1616, Fioretti, Tiziana, Randles, Michael, Cozzuto, Luca, Rajeeve, Vinothini ORCID: 0000-0002-6361-4291, Cevenini, Armando, Austin, Michael J ORCID: 0000-0003-4218-0284, Esposito, Gabriella, Ponomarenko, Julia et al (show 7 more authors)
(2023)
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Oncogene, 42 (50).
pp. 3670-3683.
Clark, Richard E ORCID: 0000-0002-1261-3299, Basabrain, Ammar A, Austin, Gemma M, Holcroft, Alison K, Loaiza, Sandra, Apperley, Jane F, Law, Christopher, Scott, Laura, Parry, Alexandra D, Bonnett, Laura ORCID: 0000-0002-6981-9212 et al (show 1 more authors)
(2021)
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.
CANCERS, 13 (9).
2155-.